Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Merck & Company (MRK)

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 202,025,024
  • Shares Outstanding, K 2,525,944
  • Annual Sales, $ 47,994 M
  • Annual Income, $ 7,067 M
  • 60-Month Beta 0.49
  • Price/Sales 3.86
  • Price/Cash Flow 10.92
  • Price/Book 5.70
Trade MRK with:

Options Overview Details

View History
  • Implied Volatility 25.80% ( +2.31%)
  • Historical Volatility 15.55%
  • IV Percentile 88%
  • IV Rank 43.12%
  • IV High 39.19% on 02/02/21
  • IV Low 15.65% on 09/03/21
  • Put/Call Vol Ratio 0.92
  • Today's Volume 28,691
  • Volume Avg (30-Day) 35,228
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 724,152
  • Open Int (30-Day) 673,706

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate 1.45
  • Number of Estimates 4
  • High Estimate 1.69
  • Low Estimate 1.22
  • Prior Year 1.32
  • Growth Rate Est. (year over year) +9.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.13 +6.46%
on 12/22/21
82.56 -3.12%
on 01/11/22
+4.44 (+5.88%)
since 12/21/21
3-Month
71.50 +11.86%
on 12/07/21
91.40 -12.49%
on 11/04/21
-1.19 (-1.47%)
since 10/21/21
52-Week
70.89 +12.82%
on 09/17/21
91.40 -12.49%
on 11/04/21
-1.20 (-1.48%)
since 01/21/21

Most Recent Stories

More News
Merck (MRK) Stock Moves -0.66%: What You Should Know

Merck (MRK) closed at $80.75 in the latest trading session, marking a -0.66% move from the prior day.

MRK : 79.98 (-0.95%)
Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer

Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to...

ONCY : 1.9100 (-3.05%)
ONC.TO : 2.36 (-4.45%)
LPTX : 2.11 (-11.72%)
GMDA : 3.24 (+9.46%)
ALXO : 15.44 (-3.92%)
MRK : 79.98 (-0.95%)
Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced the publication of results from the Phase 3 KEYNOTE-775/Study 309 trial in the January 19, 2022 edition of...

MRK : 79.98 (-0.95%)
Frank Clyburn to Leave Merck

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Frank Clyburn, executive vice president and president, Human Health, will leave Merck on Feb. 1, 2022, to assume...

MRK : 79.98 (-0.95%)
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the final results from the Phase 3 KEYNOTE-394 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, plus best...

MRK : 79.98 (-0.95%)
Catalyst Pharmaceuticals: A Biotech Stock Worth Owning

Biopharmaceutical company Catalyst Pharmaceuticals (CPRX) has been advancing with the help of its product, FIRDAPSE. Furthermore, its top and bottom line grew in its last reported quarter. So, let’s...

CPRX : 5.54 (-2.64%)
JNJ : 164.87 (-0.23%)
MRK : 79.98 (-0.95%)
GSK : 45.10 (+0.49%)
Will Moderna (MRNA) Continue to Ride on Vaccine Sales in 2022?

Although Moderna's (MRNA COVID-19 vaccine sales are likely to rise, we expect pipeline updates to be the key catalyst for share price movement in 2022.

AZN : 59.10 (-1.78%)
MRK : 79.98 (-0.95%)
VRTX : 228.08 (-0.23%)
MRNA : 160.07 (-4.45%)
AstraZeneca (AZN) Enhertu sBLA Receives FDA Priority Tag

AstraZeneca's (AZN) sBLA seeks approval of Enhertu for unresectable and/or metastatic HER2-positive metastatic breast cancer previously treated with an anti-HER2-based regimen.

AZN : 59.10 (-1.78%)
RHHBY : 49.1200 (-0.57%)
PFE : 52.79 (-2.33%)
MRK : 79.98 (-0.95%)
Zacks Industry Outlook Highlights: Roche, Pfizer, AbbVie and Merck

Roche, Pfizer, AbbVie and Merck are highlighted in this Industry Outlook article.

RHHBY : 49.1200 (-0.57%)
PFE : 52.79 (-2.33%)
MRK : 79.98 (-0.95%)
ABBV : 131.98 (-0.79%)
Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced the signing of a long-term supply agreement with the United Nations Children’s Fund...

MRK : 79.98 (-0.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies...

See More

Key Turning Points

3rd Resistance Point 83.53
2nd Resistance Point 82.53
1st Resistance Point 81.25
Last Price 79.98
1st Support Level 78.97
2nd Support Level 77.97
3rd Support Level 76.69

See More

52-Week High 91.40
Fibonacci 61.8% 83.57
Fibonacci 50% 81.15
Last Price 79.98
Fibonacci 38.2% 78.72
52-Week Low 70.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar